LAWRENCE, Mass., Nov. 3, 2010 /PRNewswire via COMTEX/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it has expanded its Medisystems® in-center product portfolio to include Vasc-Alert’s automated vascular access surveillance product. Pursuant to the terms of the strategic Agreement with Vasc-Alert LLC, the service can be purchased exclusively from NxStage in the United States.
Vasc-Alert, a patented medical device, uses computer technology to analyze standard treatment data taken during each patient’s scheduled hemodialysis treatments to screen for vascular access dysfunction. By monitoring the data for increasing pressure trends, Vasc-Alert identifies patients who are at risk of developing a stenosis that may decrease the effectiveness of treatment or put the access site at risk of thrombosis–a blockage that prevents the flow of blood through the access and can precipitate significant medical interventions such as thrombectomy and access revision. Weekly reports that identify at-risk patients are issued to the dialysis provider and allow the dialysis staff to proactively schedule further testing on the access. Earlier detection of access issues has the potential to lead to improved access patency, fewer hospitalizations, fewer missed treatments, and less pain, anxiety and inconvenience for patients.
Vasc-Alert offers significant ease-of-use benefits to clinics and staff. In contrast to other methodologies, no staff time is consumed in performing access surveillance testing and patient treatments are not impacted in any way. Importantly, the readily accessible reports enable centers to comply with recent Centers for Medicare & Medicaid Services (CMS) access surveillance requirements.
Complications in vascular access are common, and are a top concern in delivering the best care to patients, said John Kennedy,President of Vasc-Alert. A growing number of centers have experienced the convenience, efficiency, and effectiveness of Vasc-Alert access surveillance. Collaborating with a world-class leader in NxStage enables us to offer our innovative solution to a larger base of customers across the United States.
NxStage strives to offer our customers leading, innovative products to better meet their needs in a constantly evolving environment, stated Joseph Turk, Senior Vice President of Commercial Operations of NxStage Medical. The Vasc-Alert service complements our innovative Medisystems product line in a timely fashion, as providers are tasked with implementing recent CMS requirements for access surveillance.
Vasc-Alert provides proactive surveillance of hemodialysis patients’ access sites by analyzing the hemodialysis machine blood flow and pressure data to derive the intra-access pressures. If the patient’s access site is determined to be at risk, an alert report is issued.
Vasc-Alert uses readily available dialysis data- therefore no additional staff time is required for data collection. An analysis is performed for each dialysis session and trends are established for each patient. This unique trending can indicate when a patient’s pressure is increasing, which may signify a problem in the access. An Alert is issued once increased pressure is detected for three consecutive treatments (KDOQIguidelines).
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company’s website at http://www.nxstage.com/.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including factors that are discussed in NxStage’s filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
SOURCE NxStage Medical, Inc.